Literature DB >> 25460330

Diffusion-weighted MRI and MR- volumetry--in the evaluation of tumor response after preoperative chemoradiotherapy in patients with locally advanced rectal cancer.

Bilge Birlik1, Funda Obuz2, Funda D Elibol2, Ahmet O Celik2, Selman Sokmen3, Cem Terzi3, Ozgul Sagol4, Sulen Sarioglu4, Ilknur Gorken5, Ilhan Oztop6.   

Abstract

PURPOSE: To determine the diagnostic performance of diffusion-weighted MRI and MR volumetry for the assessment of tumor response after preoperative chemoradiotherapy (CRT) in patients with locally advanced rectal cancer.
MATERIALS AND METHODS: Forty-three patients with rectal cancer who underwent preoperative CRT were prospectively examined for the study. This prospective study was approved by our institutional review board. DW- and high resolution T2-weighted imaging were performed before and after therapy. Two different diffusion gradients (b = 0 and b = 600, then separately b = 0 and b = 1000) were applied. The mean tumor volume and mean ADC values were measured before and after therapy. To evaluate the responders and nonresponders to neoadjuvant CRT, two criteria, ypT stage determined in the pathologic examination after treatment and histopathologic tumor regression grade (Ryan), were used as reference standards. The patients with a lower ypT stage than T stage in the first MRI before neoadjuvant CRT were evaluated as the responder group, while the patients with a higher or the same ypT stage relative to the first MRI T stage were evaluated as the nonresponder group. According to Ryan tumor regression grade, grade 1 was evaluated as the responders, whereas grades 2 and 3 were evaluated as the nonresponder group. The percentage ADC increase and percentage tumor volume regression were compared between the responders and nonresponders using two reference standards: T downstaging and tumor regression grade (TRG).
RESULTS: Before CRT, the mean tumor ADC in the responder group was significantly lower than that in the nonresponder group (p < 0.001). At the end of CRT, the mean percentage of tumor ADC change in the responder group was significantly higher than that in the nonresponder group. The percentage tumor volume regression of the responders was significantly higher than that of the nonresponders (p = 0.001). The cut-off ADC value for discriminating between the responders and nonresponders after treatment was determined to be (b = 600) 1.03 × 10(-3)mm(2)/s and the sensitivity, 71%; specificity, 79%; accuracy, 74%; positive predictive value, 81%; negative predictive value, 68% respectively. The cut-off value for discriminating between the responders and the nonresponders after treatment was determined for b = 1000 as 1.20 × 10(-3)mm(2)/s and the sensitivity, 42%; specificity, 84%; accuracy, 60%; positive predictive value, 77%; negative predictive value, 53%.
CONCLUSION: The increase in the mean tumor ADC and percentage tumor volume regression in patients with rectal cancer treated with preoperative CRT was correlated with good response. DW MR imaging is a promising non-invasive technique that can help predict and monitor early therapeutic response in patients with rectal cancer who undergo CRT.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diffusion MR imaging; Locally advanced rectal cancer; MR-volumetry; Neoadjuvant chemoradiotherapy; Tumor response

Mesh:

Year:  2014        PMID: 25460330     DOI: 10.1016/j.mri.2014.08.041

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  18 in total

Review 1.  Diffusion-weighted imaging in rectal cancer: current applications and future perspectives.

Authors:  Niels W Schurink; Doenja M J Lambregts; Regina G H Beets-Tan
Journal:  Br J Radiol       Date:  2019-03-05       Impact factor: 3.039

2.  Combined value of apparent diffusion coefficient-standardized uptake value max in evaluation of post-treated locally advanced rectal cancer.

Authors:  Davide Ippolito; Davide Fior; Chiara Trattenero; Elena De Ponti; Silvia Drago; Luca Guerra; Cammillo Talei Franzesi; Sandro Sironi
Journal:  World J Radiol       Date:  2015-12-28

3.  Development and validation of an MRI-based radiomic nomogram to distinguish between good and poor responders in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy.

Authors:  Jia Wang; Xuejun Liu; Bin Hu; Yuanxiang Gao; Jingjing Chen; Jie Li
Journal:  Abdom Radiol (NY)       Date:  2020-11-05

4.  Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial).

Authors:  Ken-Ichi Okada; Manabu Kawai; Seiko Hirono; Fumiyoshi Kojima; Kensuke Tanioka; Masaki Terada; Motoki Miyazawa; Yuji Kitahata; Yoshifumi Iwahashi; Masaki Ueno; Shinya Hayami; Shin-Ichi Murata; Toshio Shimokawa; Hiroki Yamaue
Journal:  Langenbecks Arch Surg       Date:  2020-01-28       Impact factor: 3.445

5.  Ability of Delta Radiomics to Predict a Complete Pathological Response in Patients with Loco-Regional Rectal Cancer Addressed to Neoadjuvant Chemo-Radiation and Surgery.

Authors:  Valerio Nardone; Alfonso Reginelli; Roberta Grassi; Giovanna Vacca; Giuliana Giacobbe; Antonio Angrisani; Alfredo Clemente; Ginevra Danti; Pierpaolo Correale; Salvatore Francesco Carbone; Luigi Pirtoli; Lorenzo Bianchi; Angelo Vanzulli; Cesare Guida; Roberto Grassi; Salvatore Cappabianca
Journal:  Cancers (Basel)       Date:  2022-06-18       Impact factor: 6.575

Review 6.  Diffusion MRI in early cancer therapeutic response assessment.

Authors:  C J Galbán; B A Hoff; T L Chenevert; B D Ross
Journal:  NMR Biomed       Date:  2016-01-15       Impact factor: 4.044

7.  Elastography and diffusion-weighted MRI in patients with rectal cancer.

Authors:  Søren R Rafaelsen; Chris Vagn-Hansen; Torben Sørensen; Jan Lindebjerg; John Pløen; Anders Jakobsen
Journal:  Br J Radiol       Date:  2015-09-24       Impact factor: 3.039

Review 8.  [Rational staging and follow-up of colorectal cancer : Do guidelines provide further help?]

Authors:  M S Juchems; J Wessling
Journal:  Radiologe       Date:  2019-09       Impact factor: 0.635

Review 9.  Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials.

Authors:  Thomas J George; Carmen J Allegra; Greg Yothers
Journal:  Curr Colorectal Cancer Rep       Date:  2015

10.  Re-Staging Following Long-Course Chemoradiotherapy For Rectal Cancer: Does It Influence Management?

Authors:  A McBrearty; K McCallion; R J Moorehead; I McAllister; K Mulholland; R Gilliland; W J Campbell
Journal:  Ulster Med J       Date:  2016-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.